加味寿胎丸联合间苯三酚注射液对先兆流产合并绒毛膜下血肿的影响

Influence of phloroglucinol combined with modified Shoutai Pills on patients with threatened abortion and subchorionic hematoma

目的 观察加味寿胎丸联合间苯三酚注射液对先兆流产合并绒毛膜下血肿(SCH)的影响。方法 将90例先兆流产合并SCH患者按照随机数字表法分为2组,对照组45例予间苯三酚注射液治疗,治疗组45例在对照组治疗基础上予加味寿胎丸。2组均治疗14 d。比较2组治疗前后血清孕酮(P)、雌二醇(E_(2))、β-人绒毛膜促性腺激素(β-HCG)及中医证候评分,比较2组腹痛消失时间、临床症状消失时间、阴道持续出血时间,并统计2组临床疗效及不良反应发生情况。结果 治疗组总有效率93.33%(42/45),对照组总有效率73.33%(33/45),治疗组临床疗效优于对照组(P<0.05)。2组治疗后血清P、E_(2)、β-HCG水平均较本组治疗前升高(P<0.05),且治疗组治疗后均高于对照组(P<0.05)。治疗组腹痛消失时间、临床症状消失时间、阴道持续出血时间均短于对照组(P<0.05)。2组治疗后中医证候各项评分及总分均较本组治疗前降低(P<0.05),且治疗组治疗后均低于对照组(P<0.05)。2组不良反应总发生率比较差异无统计学意义(P>0.05)。结论 加味寿胎丸联合间苯三酚注射液治疗先兆流产合并SCH可有效提高患者激素水平,改善临床症状,减少出血,安全有效。

Objective To investigate the effect of phloroglucinol combined with modified Shoutai Pills on threatened abortion(TA) patients with subchorionic hematoma(SCH). Methods Totally 90 TA patients with SCH were randomized 1∶1 to receive phloroglucinol injection(the control group) or modified Shoutai pill+ phloroglucinol injection(the treatment group) for 14 days. The serum indexes(progesterone [P], estradiol [E_(2)], β-human chorionic gonadotropin [β-HCG]), traditional Chinese medicine(TCM) syndrome score, the disappearance time to abdominal pain and clinical symptoms, and the duration of vaginal bleeding before and after treatment were compared between groups. The curative effect and incidence of adverse reactions were assessed. Results The overall effective rate in the treatment group was better than that in the control group(93.33% [42/45] vs 73.33% [33/45], [P<0.05], respectively). After treatment, the levels of P, E_(2), β-HCG in the both groups were increased(P<0.05), which were increased in the treatment group as compared with the control group(P<0.05);the disappearance time to abdominal pain and clinical symptoms, and the duration of vaginal bleeding in the treatment group were shorter than those in the control group(P<0.05);TCM syndrome scores in the both groups were decreased(P<0.05), the reduction in the treatment group was more prevalent relative to the control group(P<0.05). None of the incidence of adverse reactions differed significantly between groups. Conclusion For TA patients with SCH, the two combination can effectively increase hormone levels, improve clinical symptoms, reduce bleeding, with safety and effectiveness.